Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant
American Journal of Medical Genetics Part A · 2024
DOI: 10.1002/ajmg.a.63489 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2024. Verfasst von William Scott und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Chronic diarrhea presents a significant challenge for managing nutritional and electrolyte deficiencies, especially in children, given the higher stakes of impacting growth and developmental consequence. Congenital secretory diarrhea (CSD) compounds this further, particularly in the case of the activating variants of the guanylate‐cyclase 2C ( GUCY2C ) gene. GUCY2C encodes for the guanylate‐cyclase 2C (GC‐C) receptor that activates the downstream cystic fibrosis transmembrane receptor (CFTR) that primarily drives the severity of diarrhea with an unclear extent of influence on other intestinal channels. Thus far, management for CSD primarily consists of mitigating nutritional, electrolyte, and volume deficiencies with no known pathophysiology‐driven treatments. For activating variants of GUCY2C , experimental compounds have shown efficacy in vitro for direct inhibition of GC‐C but are not currently available for clinical use. However, Crofelemer, a CFTR inhibitory modulator with negligible systemic absorption, can theoretically help to treat this type of CSD. Herein, we describe and characterize the clinical course of a premature male infant with a de novo missense variant of GUCY2C not previously reported and highly consistent with CSD. With multi‐disciplinary family‐directed decision‐making, a treatment for CSD was evaluated for the first time to our knowledge with Crofelemer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- School of Pharmacy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Pharmacy, Children's Wisconsin, Milwaukee, Wisconsin, USA.
- Napo Pharmaceuticals, Inc, San Francisco, California, USA.
ORCID-Profile: William Scott
Zitieren
APA
Scott, W., Wong, I. G. Y., Cramer, J., Horton, D., Basel, D., Teng, R. J., Muriello, M., & Elkadri, A. (2024). Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63489
Vancouver
Scott W, Wong IGY, Cramer J, Horton D, Basel D, Teng RJ, et al. Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant. American Journal of Medical Genetics Part A. 2024. doi:10.1002/ajmg.a.63489
BibTeX
@article{Scott2024,
author = {Scott, William and Wong, Ian Guo Yi and Cramer, Jesse and Horton, Darlene and Basel, Donald and Teng, Ru-Jeng and Muriello, Michael and Elkadri, Abdul},
title = {Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant},
journal = {American Journal of Medical Genetics Part A},
year = {2024},
doi = {10.1002/ajmg.a.63489}
}
EUVIMED